Supreme PLC



Strong trading shows benefit of diversified portfolio

In a Trading Update for the year to 31st March 2025, Supreme reports that the Group traded strongly, supported by acquisitions and underpinned by cost management. Supreme expects FY25 revenue of c.£235.0m and (adj.) EBITDA of "at least" £40.0m; they also expect FY26 (adj.) EBITDA in line with market expectations¹.

Supreme notes development of a number of new sales opportunities following from the acquisition of Clearly Drinks (June 2024), accessing the soft drinks sector, and Typhoo Tea (December 2024), enabling entry into the market for hot beverages. Having spent £25.0m on acquisitions during the period, the Group notes that it ended the year net cash positive (pre-IFRS 16-basis).

Shift to refillable vapes

Sales in the Vape business category are reported in line with Supreme's own outlook ahead of the June 1st ban on disposable vapes, maintained through the combination of an established distribution profile and investment in rechargeable pod vaping devices. As recently reported², research by University College London (UCL 'Smoking Alcohol Toolkit Study'³), shows that "more people are turning to refillable, reusable devices" rather than stopping vaping altogether; matching the assumptions built into Supreme's strategy in response to the announcement of the government ban on disposable vapes.

Outlook, inclusive of acquisitions

We have revised our FY25 estimates in line with company guidance, reducing our revenue outlook by 2.1% from £240.2m; our FY25 (adj.) EBITDA outlook is maintained at £40.0m supported by the improvement in profitability resulting from the shift to refillable vapes. However, our FY26 outlook is based on a conservative view of vaping revenue; we estimate £115.0m compared to £132.2m for FY25E and £139.8m recorded in FY24. We calculate the contribution to revenue from acquired operations at £24.4m in FY25 (pro rata) and in FY26, £44.5m, with an overall 52% of total revenue derived from non-vape products. This, in particular illustrates the speed with which Supreme has adapted to changes in the vaping market, also building on its unified distribution and market network reach. Typhoo recorded £24.1m in one-off costs resulting from extensive damage to its Merseyside facilities in 2023; our estimates also include provision for costs assumed for the full integration of Typhoo operations.

Shares still on attractive ratings

On our outlook, Supreme trades on an attractive FY26 EV/EBITDA of 5.5x. Overall, there is no change to our (adj.) EBITDA estimates and no change to our Fair Value of 225p/share.

Financial outlook					
Yr to March 31 (£m)	2022	2023	2024	2025E	2026E
Revenue	130.8	155.6	221.2	235.1	240.0
EBITDA (adj)	21.1	19.4	38.1	40.0	36.0
EPS (adj, p)	12.4	11.2	20.2	20.1	19.7
DPS (p)	2.2	4.6	3.7	5.2	4.6
Net debt / (cash) ⁴	1.8	11.1	1.8	(7.4)	(16.0)
EV/EBITDA	9.3x	10.1x	5.2x	4.9x	5.5x
P/E	13.4x	14.9x	8.2x	8.3x	8.4x
Div yield	1.3%	2.8%	2.2%	3.1%	2.8%

Source: Company data. Equity Development estimates. ¹ At time of announcement, FY 26 analysts' consensus (adj.) EBITDA of c.£36.6m. ² BBC News 16th April. ³ www.ucl.ac.uk/epidemiology-health-care/smoking-alcohol-toolkit-study 2025. ⁴ Net debt is pre-IFRS 16.

23 April 2025

Company Data

EPIC	SUP.L
Price (last close)	166p
52 weeks Hi/Lo	210p/120p
Market cap	£195m
ED Fair Value/share	225p



Source: Investing.com

Description

Supreme Imports is a leading European and UK manufacturer, supplier and brand owner of fastmoving consumer products in six categories: Vaping, Sports Nutrition & Wellness, Batteries, Lighting, Branded Distribution (household goods) and Soft Drinks. The Group supplies leading brands such as Aldi, Amazon, Asda, B&M, Costcutter, Halfords, Home Bargains, Iceland, Morrisons, The Range, Sainsbury's, Tesco, Waitrose and, in addition, HM Prison & Probation Service. Supreme acquired Typhoo Tea in December 2024.

Next event

FY25 results: 1st July 2025

Mike Jeremy (Analyst) 0207 065 2690 mike.jeremy@equitydevelopment.co.uk Hannah Crowe

0207 065 2692 hannah@equitydevelopment.co.uk

Earnings outlook

The following summarises our earnings outlook with the FY26 contribution from non-vaping products at 52.1% of total revenue, including contributions from acquired operations:

- Clearly Drinks: FY25 £18.0m, FY26, £24.5m.
- Typhoo Tea: FY25, £6.4m, FY26, £20.0m.

Revised outlook						
Yr to 31 March (£m)	FY25 Old	FY25 New	%/bp	FY26 Old	FY26 New	%/bp
Revenue	240.2	235.1	-2.1%	231.0	239.5	3.7%
Gross inc forex	71.9	72.7	1.1%	69.8	74.8	7.2%
Mrg	29.9%	30.9%	98	30.2%	31.2%	102
EBIT (rptd)	31.2	33.2	6.4%	28.8	28.9	0.4%
EBIT (adj)	33.6	33.6	0.0%	29.8	29.9	0.4%
Mrg	14.0%	14.3%	30	12.9%	12.5%	(41)
EBITDA (rptd)	37.6	39.6	5.3%	35.2	35.3	0.3%
EBITDA (adj)	40.0	40.0	0.0%	36.3	36.3	0.0%
Mrg	16.7%	17.0%	36	15.7%	15.1%	(51)
PBT (rptd)	29.8	31.8	6.7%	27.4	27.5	0.4%
PBT (adj)	32.2	32.2	0.0%	28.4	28.5	0.4%

Source: Company data. Equity Development estimates.

As illustrated below, the contribution from diversification into new businesses has continued to offset the impact of changes in the marketing of vaping products, illustrating the speed with which Supreme has adapted to changing market conditions.



Business categories revenue outlook to FY26



Comparative valuation update

Below illustrates Supreme's current valuation (PE vs EV/(adj.) EBITDA) and ED Fair Value compared to the average⁵ of peers in sectors which match Supreme's product lines, and an indicative valuation based on the application of peer group sector multiples to Supreme's (adj.) EBITDA outlook, pro rata to business segment gross profit contribution (e.g. Supreme Batteries segment contributes 7.3% of FY25 E gross, which is applied to FY25E (adj.) EBITDA (£40.0m E) at the 'consumer' segment average multiple of 12.7x). ⁵ market cap weighted.



Source: Koyfin. Equity Development estimates.

Indicative valuation range based on product segment peer group average multiples. The valuation range indicates an average of 315p/share compared to ED FV of 225p/share.

Supreme indicative valuation range based on peer group multiples

Peer group constituents	FY25E (ad.) EBITDA	% of gross	Peer	EV/EBITDA	EV £m
	Batteries	6.4%	Consumer	12.7x	32.5
Consumer:	Lighting	9.2%	Consumer	12.7x	46.7
Unilever PLC	Vaping	64.1%	Tobacco	8.7x	224.3
The Procter & Gamble Company	Sports Nutrition	6.8%	Consumer	12.7x	34.7
Nestlé S.A.	Branded Distribution	1.9%	Consumer	12.7x	9.5
Walmart Inc.	Soft Drinks	8.8%	Soft Drinks	13.9x	49.1
	EV indicated (£m)				396.7
Tobacco:	Indicated EV/EBITDA multiple				9.9x
Reckitt Benckiser Group plc	Net debt (£m)				1.82
British American Tobacco p.l.c.	FY25 E indicated equity (£m)				398.5
Philip Morris International Inc.	Per share value indicated (p)				339.7
Altria Group Inc.					
Imperial Brands PLC	FY26E (adj.) EBITDA	% of gross	Peer	EV/EBITDA	EV £m
	Batteries	6.1%	Consumer	12.7x	27.9
Soft Drinks:	Lighting	8.4%	Consumer	12.7x	38.5
PepsiCo Inc.	Vaping	58.1%	Tobacco	8.7x	182.7
Fevertree Drinks PLC	Sports Nutrition	8.0%	Consumer	12.7x	36.4
Carlsberg Britvic	Branded Distribution	1.0%	Consumer	12.7x	4.7
A.G. BARR p.l.c.	Soft Drinks	9.8%	Soft Drinks	13.9x	48.8
The Coca-Cola Company	EV indicated (£m)				339.1
	Indicated EV/EBITDA multiple				9.4x
	Net debt (£m)				1.82
	FY26 E indicated equity (£m)				340.87
	Per share value indicated (p)				290.5
	Average of FY24 - FY25 per share	e (p)			315.1

Source: Koyfin. Equity Development estimates.



P&L

£m	H1 23	H2 23	H1 24	H2 24	H1 25	FY23	FY24	FY25E	FY26E
Batteries	15.7	23.9	15.9	24.6	17.4	39.5	40.5	38.0	38.0
Lighting	6.2	9.3	7.5	9.0	8.1	15.4	16.5	16.0	16.0
Vaping	31.8	41.7	42.1	40.7	36.6	76.1	82.8	73.2	74.0
Sports Nutrition & Wellness	7.6	9.1	8.9	9.0	9.5	16.7	18.0	19.5	21.0
Branded Distribution	3.4	4.4	30.6	32.9	34.4	7.8	63.5	64.0	46.0
Soft Drinks								18.0	24.5
Revenue	64.6	88.4	105.1	116.2	113.0	155.6	221.2	235.1	239.5
Gross Sum	17.6	22.0	27.9	34.5	33.5	39.6	62.4	71.2	73.3
Mrg	27.3%	24.9%	26.6%	29.7%	29.6%	25.4%	28.2%	30.3%	30.6%
Gross inc forex	18.2	22.7	28.5	35.0	34.1	40.9	63.5	72.7	74.8
Mrg	28.1%	25.7%	27.2%	30.1%	30.1%	26.3%	28.7%	30.9%	31.2%
Sum Op-ex	(13.4)	(14.8)	(15.5)	(16.1)	(20.6)	(28.2)	(31.5)	(39.5)	(45.9)
One-off costs	(1.4)	0.6	0.5	(1.1)	(1.8)	(0.8)	(0.6)	(0.4)	(1.0)
One off gain	0.0	0.0	0.0	0.0	0.0	2.8	0.0	0.0	0.0
EBIT Reported	4.8	7.9	13.1	18.9	13.5	15.4	32.0	33.2	28.9
EBIT Adjusted	6.2	7.3	12.6	20.1	15.3	16.3	32.6	33.6	29.9
Mrg	9.6%	8.2%	12.0%	17.3%	13.6%	10.5%	14.7%	14.3%	12.5%
Depreciation	(1.4)	(0.8)	(1.8)	(2.0)	(2.3)	(2.2)	(3.8)	(4.9)	(4.9)
Amortisation	(0.5)	(0.4)	(0.8)	(0.9)	(0.9)	(0.9)	(1.7)	(1.5)	(1.5)
EBITDA Reported	§	11.9	15.7	21.8	16.6	18.6	37.5	39.6	35.3
EBITDA Adjusted	8.1	11.3	15.2	22.9	18.5	19.4	38.1	40.0	36.3
Mrg	12.6%	12.8%	14.5%	19.7%	16.3%	12.5%	17.2%	17.0%	15.1%
Financial income	0.00	0.03	0.00	0.14	0.12	0.03	0.15	0.00	0.00
Financial expense	(0.4)	(0.6)	(0.8)	(1.3)	(0.7)	(1.0)	(2.0)	(1.4)	(1.4)
PBT Reported	4.4	10.0	12.3	17.8	12.9	14.4	30.1	31.8	27.5
PBT Adjusted	5.8	9.4	11.8	18.9	14.7	15.3	30.7	32.2	28.5
Тах	(1.1)	(1.4)	(3.0)	(4.7)	(2.2)	(2.5)	(7.7)	(8.0)	(6.9)
Reported tax rate	25.2%	13.5%	24.5%	26.2%	17.1%	20.0%	25.5%	25.0%	25.0%
PAT Reported	3.3	8.8	9.3	13.2	10.7	12.1	22.4	23.8	20.6
PAT Adjusted	4.7	8.2	8.8	14.3	12.5	12.9	23.0	24.2	21.6
Amortisation & tax items	0.5	(0.1)	0.2	0.0	0.5	1.8	2.6	4.4	3.3
PAT Adjusted	5.2	8.7	9.5	13.2	13.0	13.8	25.0	28.2	23.9
Diluted wtd. av. shares (m)	121.1	123.5	124.0	123.7	120.4	123.5	123.7	120.4	120.4
EPS rptd. basic (p)	2.8	7.5	7.9	11.2	9.2	10.3	19.1	20.4	17.7
EPS adj. dil. (p)	4.3	7.0	7.7	10.6	10.8	11.2	20.2	23.4	19.8



Cashflow

Yr to March 31 (£m)	H1 23	H2 23	H1 24	H2 24	H1 25	FY23	FY24	FY25E	FY26E
PAT Reported	3.3	8.7	9.3	13.2	10.7	12.0	22.4	23.8	20.6
One-off items	0.4	0.5	(0.5)	0.7	1.8	0.8	0.2	0.4	1.0
Depreciation	1.4	0.8	1.8	2.0	2.3	2.2	3.8	4.9	4.9
Amortisation	0.5	0.4	0.8	0.9	0.9	0.9	1.7	1.5	1.5
Тах	1.1	1.4	3.0	4.7	2.2	2.5	7.7	8.0	6.9
Finance/other	0.4	(0.4)	0.4	2.1	0.1	(0.0)	2.4	0.0	1.4
Operating Cash Flow	7.0	11.3	14.8	23.4	17.9	18.4	38.2	38.6	36.3
(Increase)/Decrease inventories	(2.2)	5.1	(5.2)	6.4	(6.8)	2.9	1.2	(12.9)	4.6
(Increase)/Decrease in receivables	(6.7)	6.0	(21.0)	6.3	3.5	(0.7)	(14.7)	6.6	(3.8)
Increase/(Decrease) in payables	8.4	(8.4)	14.4	(6.7)	(2.7)	(0.0)	7.7	1.7	(2.7)
Movement in working capital	(0.5)	2.7	(11.8)	6.0	(5.9)	2.2	(5.8)	(4.6)	(2.0)
Cash generated by operations	6.5	14.1	2.9	29.5	12.0	20.6	32.4	34.0	34.3
Tax (paid)/received	(1.7)	0.3	(2.5)	(2.8)	(0.7)	(1.3)	(5.3)	(8.0)	(6.9)
Net cash from operations	4.9	14.4	0.4	26.7	11.3	19.3	27.1	26.0	27.4
Interest received	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangibles	0.0	0.0	0.0	(0.1)	(0.1)	0.0	(0.1)	0.0	0.0
PPE	(0.5)	(0.7)	(2.8)	(2.5)	(1.1)	(1.3)	(5.3)	(2.0)	(2.2)
Acquisition	(10.1)	0.1	0.0	(2.5)	(15.6)	(10.1)	(2.5)	(25.2)	0.0
Sale of PPE	0.0	4.0	0.1	0.1	0.9	4.0	0.1	0.0	0.0
Net cash used in investing	(10.7)	3.2	(5.2)	(6.1)	(15.7)	(7.6)	(11.3)	(27.2)	(2.2)
Net OpFCF	(5.9)	17.6	(4.8)	20.6	(4.4)	11.7	15.8	(1.2)	25.2
Borrowings (net)	12.5	(13.8)	5.5	(9.9)	0.0	(1.3)	(4.4)	0.0	0.0
Share issue	0.0	0.3	0.0	(1.0)	0.0	0.3	(1.0)	0.0	0.0
Interest paid	(0.2)	(0.6)	(0.4)	0.4	(0.4)	(0.8)	0.0	0.0	0.0
Leases	(0.5)	(0.5)	(0.5)	(0.7)	(0.7)	(1.0)	(1.2)	(2.5)	(2.5)
Dividend	(4.4)	(0.9)	(2.6)	(1.8)	(3.7)	(5.4)	(4.3)	(6.1)	(5.4)
Net cash from financing	7.3	(15.5)	2.1	(13.7)	(4.9)	(8.2)	(11.6)	(8.6)	(7.9)
Net change cash	1.5	2.0	(2.7)	6.8	(9.3)	3.5	4.2	(9.7)	17.3
Cash start	3.9	5.4	7.5	4.9	11.6	3.9	7.5	11.6	1.9
Forex	0.0	0.1	0.0	(0.1)	(0.1)	0.1	(0.1)	0.0	0.0
Cash end	5.4	7.5	4.9	11.6	2.3	7.5	11.6	1.9	19.2



Balance sheet

Yr to March 31 (£m)	H1 23	H2 23	H1 24	H2 24	H1 25	FY23	FY24	FY25E	FY26E
Intangible assets	14.1	15.3	14.4	13.7	19.3	15.3	13.7	17.8	16.3
PPE net	3.6	5.2	7.1	7.5	15.4	5.2	7.5	13.6	10.9
RoU	1.7	15.6	14.7	13.9	12.7	15.6	13.9	13.9	13.9
Investments	0.6	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0
Sum Fixed Assets	20.1	36.1	36.2	35.1	47.6	36.1	35.1	45.3	41.1
Inventories	30.6	25.6	30.8	24.4	32.3	25.6	24.4	37.4	32.8
Trade receivables	26.9	20.9	41.9	35.6	35.1	20.9	35.6	29.0	32.8
Tax assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial insts	0.8	0.0	0.9	0.0	0.3	0.0	0.0	0.0	0.0
Cash	5.4	7.5	4.9	11.6	2.3	7.5	11.6	1.9	19.2
Sum Current Assets	63.8	54.0	78.6	71.7	70.1	54.0	71.7	68.2	84.8
Total Assets	83.8	90.1	114.9	106.8	117.7	90.1	106.8	113.6	125.9
Trade payables	(31.8)	(26.1)	(39.8)	(27.3)	(28.4)	(26.1)	(27.3)	(29.0)	(26.2)
Bank borrowings	(0.4)	(4.3)	(9.7)	0.0	(1.0)	(4.3)	0.0	0.0	0.0
Tax, Other	(0.8)	(3.2)	(3.2)	(5.5)	(8.9)	(3.2)	(5.5)	(5.5)	(5.5)
Sum Current Liabilities	(33.0)	(34.3)	(52.7)	(34.0)	(38.2)	(34.3)	(34.0)	(35.7)	(33.0)
Total Assets less Current Liabilities	50.8	55.8	62.1	72.7	79.5	55.8	72.7	77.8	92.9
Bank borrowings non-current	(17.8)	(14.3)	(13.8)	(13.4)	(13.1)	(14.3)	(13.4)	(13.1)	(13.1)
Tax/Provisions	(0.3)	(1.6)	(0.6)	(1.3)	(1.1)	(1.6)	(1.3)	(1.3)	(1.3)
Sum Long-term liabilities	(19.8)	(15.9)	(14.3)	(14.8)	(14.2)	(15.9)	(14.8)	(13.4)	(12.4)
Total liabilities	(52.9)	(50.2)	(67.1)	(48.8)	(52.4)	(50.2)	(48.8)	(49.1)	(45.4)
Net Assets	31.0	40.0	47.8	58.0	65.3	40.0	58.0	64.4	80.5
Share Capital	11.7	11.7	11.7	11.7	11.7	11.7	11.7	11.7	11.7
Share Premium	7.2	7.4	7.4	7.4	7.6	7.4	7.4	(10.3)	(18.1)
Capital Reserve	(22.0)	(22.0)	(22.0)	(22.0)	(22.0)	(22.0)	(22.0)	(22.0)	(22.0)
Retained earnings	31.9	39.8	46.5	56.8	63.8	39.8	56.8	85.1	109.0
Equity	31.0	40.0	47.8	58.0	65.3	40.0	58.0	64.4	80.5
Net debt / (cash) pre-IFRS 16	12.9	11.1	18.6	1.8	11.8	11.1	1.8	(1.9)	(19.2)



Contacts

Andy Edmond Direct: 020 7065 2691 Tel: 020 7065 2690 andy@equitydevelopment.co.uk

Hannah Crowe Direct: 0207 065 2692 Tel: 0207 065 2690 hannah@equitydevelopment.co.uk

Equity Development Limited is regulated by the Financial Conduct Authority

Disclaimer

Equity Development Limited ('ED') is retained to act as financial adviser for its corporate clients, some or all of whom may now or in the future have an interest in the contents of this document. ED produces and distributes research for these corporate clients to persons who are not clients of ED. In the preparation of this report ED has taken professional efforts to ensure that the facts stated herein are clear, fair and not misleading, but makes no guarantee as to the accuracy or completeness of the information or opinions contained herein.

Any reader of this research should not act or rely on this document or any of its contents. This report is being provided by ED to provide background information about the subject of the research to relevant persons, as defined by the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever.

Research produced and distributed by ED on its client companies is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent as defined by the FCA but is 'objective' in that the authors are stating their own opinions. This document is prepared for clients under UK law. In the UK, companies quoted on AIM are subject to lighter due diligence than shares quoted on the main market and are therefore more likely to carry a higher degree of risk than main market companies.

ED may in the future provide, or may have in the past provided, investment banking services to the subject of this report. ED, its directors or persons connected may at some time in the future have, or have had in the past, a material investment in the Company. ED, its affiliates, officers, directors and employees, will not be liable for any loss or damage arising from any use of this document to the maximum extent that the law permits.

More information is available on our website <u>www.equitydevelopment.co.uk</u>

Contact: <u>info@equitydevelopment.co.uk</u> | 020 7065 2690